Trial Profile

A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults With COVID-19

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 25 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Molnupiravir (Primary) ; Molnupiravir (Primary)
Indications COVID 2019 infections; COVID-19 respiratory infection
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms MK-4482-001; MOVe-IN
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

26 Jan 2022 This trial has been completed in Poland, according to European Clinical Trials Database record.
04 Dec 2021 This trial has been completed in Sweden, according to European Clinical Trials Database record.
09 Aug 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com